Javeed Froozan’s corporate development experience spans over 25 years in early stage, growth, and large biopharma and health tech firms. This includes acquiring companies, products and technologies in over $150 million in transaction value, strategic sales, fundings and monetization’s in excess of $100 million to develop and launch new products and enabling two IPOs in excess of $50 million each. Presently, Mr. Froozan leads the business, alliance, and portfolio management activities of the LLS Therapy Acceleration Program® (LLS TAP) venture philanthropy initiative and supports LLS biomedical grant research and other precision medicine and patient focused programs. LLS funding transactions include private placement, equity, convertible note, public offering, research funding, and revenue share agreements with companies and research institutions developing novel therapeutics, diagnostics, and digital health services. Prior to LLS, Mr. Froozan was at Emergent BioSolutions in its 10x revenue and market cap growth phase from 2003-2015 including leading the acquisition of Trubion Pharmaceuticals. He managed Emergent’s alliance with Pfizer to develop oncology and auto-immune therapeutic candidates including negotiating an agreement enabling the development of the CD20 biosimilar, RUXIENCETM (rituximab-pvvr), and to develop NuThraxTM, a novel, anthrax vaccine adjuvanted with CPG-7909. His work also includes benchmarking technology transfer and venture creation and fostering investment and job creation using state and local economic incentives to acquire corporate headquarters, R&D facilities, and a USG BARDA public-private Center of Innovation Advance Development and Manufacturing. He has provided pro-bono guidance to entrepreneurs and scientists, advised local governments on economic planning for the Life Sciences industry, and research institutions on the commercial potential of technological innovations. Mr. Froozan has a B.S. in Biology and M.B.A. in Economics & Finance from The University of Michigan.